ArticleActa pharmaceutica Sinica. B2018
Beneficial effects of
Article in Acta pharmaceutica Sinica. B, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 60 citations in OpenAlex.
- Kang Ru Plus reverses osimertinib resistance in lung adenocarcinoma via suppression of EGFR/PI3K/AKT signaling.American journal of cancer research · 2026Article
- An anti-complement homogeneous polysaccharide fromActa pharmaceutica Sinica. B · 2025Article
- Rapid Analysis of Aristolochic Acids and Aristolactams in Houttuyniae Herba by LC-MS/MS.Molecules (Basel, Switzerland) · 2022Article
- Nutraceutical prospects ofFood bioscience · 2022Article
- Structural Characterization and Biological Activity of Polysaccharides from Stems ofFoods (Basel, Switzerland) · 2022Article
- Pharmacological Effects ofPharmaceuticals (Basel, Switzerland) · 2022Review
- Network Pharmacology and Molecular Docking Elucidate the Underlying Pharmacological Mechanisms of the HerbViruses · 2022Article
- Combination of pseudoephedrine and emodin ameliorates LPS-induced acute lung injury by regulating macrophage M1/M2 polarization through the VIP/cAMP/PKA pathway.Chinese medicine · 2022Article
- Plant polysaccharides with anti-lung injury effects as a potential therapeutic strategy for COVID-19.Frontiers in pharmacology · 2022Review
- Antiosteoporosis Studies of 20 Medicine Food Homology Plants Containing Quercetin, Rutin, and Kaempferol: TCM Characteristics,Evidence-based complementary and alternative medicine : eCAM · 2022Review
- Identifying Active Substances and the Pharmacological Mechanism ofEvidence-based complementary and alternative medicine : eCAM · 2022Article
- Berberine Ameliorates Inflammation in Acute Lung Injury via NF-κB/Nlrp3 Signaling Pathway.Frontiers in nutrition · 2022Article
- Natural products provide a new perspective for anti-complement treatment of severe COVID-19: a review.Chinese medicine · 2021Review
- Human coronaviruses and therapeutic drug discovery.Infectious diseases of poverty · 2021Review
- Review
- Understanding COVID-19 in Wuhan From the Perspective of Cold-Dampness: Clinical Evidences and Mechanisms.Frontiers in medicine · 2021Review
- Upregulation of matrix metalloproteinase 9 (MMP9)/tissue inhibitor of metalloproteinase 1 (TIMP1) and MMP2/TIMP2 ratios may be involved in lipopolysaccharide-induced acute lung injury.The Journal of international medical research · 2020Article
- MicroRNA-31-5p Exacerbates Lipopolysaccharide-Induced Acute Lung Injury via Inactivating Cab39/AMPKOxidative medicine and cellular longevity · 2020Article
- COVID-19: General Strategies for Herbal Therapies.Journal of evidence-based integrative medicineArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.